PTGX
Protagonist Therapeutics Inc Earnings
$52.83
Earnings Summary
Revenue | $28.32Mn |
Net Profits | $-11.66Mn |
Net Profit Margins | -41.15% |
PE Ratio | 67.04 |
Protagonist Therapeutics Inc’s revenue fell -88.89% since last year same period to $28.32Mn in the Q1 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -83.4% fall in its revenue since last 3-months.
Protagonist Therapeutics Inc’s net profit fell -105.62% since last year same period to $-11.66Mn in the Q1 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -108.85% fall in its net profits since last 3-months.
Protagonist Therapeutics Inc’s net profit margin fell -150.6% since last year same period to -41.15% in the Q1 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -153.33% fall in its net profit margins since last 3-months.
Protagonist Therapeutics Inc’s price-to-earnings ratio after this Q1 2025 earnings stands at 67.04.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Current Year | -0.6 |
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.6 - a -3.11% fall from last quarter’s estimates.
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.6.
Key Ratios
Earning Per Share (EPS) | 0 |
Protagonist Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Protagonist Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2025-07-31 | -0.58 | 0 | 100% |
2025-11-05 | -0.6 | 0 | 100% |
2025-05-06 | 0.11 | -0.19 | -272.73% |
